Italia markets closed
FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
62.411,48 +871,81 (+1,42%)
Illumina, Inc. (ILMN)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Dopo ore:
| Chiusura precedente | 117,30 |
| Aperto | 118,56 |
| Denaro | 120,39 x 200 |
| Domanda | 120,56 x 200 |
| Min-Max giorno | 117,76 - 123,87 |
| Intervallo di 52 settimane | 86,58 - 190,31 |
| Volume | |
| Media Volume | 2.727.321 |
| Capitalizzazione | 19,184B |
| Beta (mensile su 5 anni) | 1,15 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -8,15 |
| Prossima data utili | 06 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 142,29 |
GlobeNewswireMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
© 2024 Yahoo. Tutti i diritti riservati.